Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05800951 · ClinicalTrials.gov registry record

Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock

A clinical trial, sponsored by Henry Ford Health System.

Active
Registry status
124
Enrollment target

NCT05800951: Active study, sponsored by Henry Ford Health System.

NCT05800951 is a clinical trial that is active but no longer recruiting, run by Henry Ford Health System. The registered enrollment target is 124 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05800951 is active but no longer recruiting, sponsored by Henry Ford Health System.

ACTIVE NOT RECRUITING
Registry status
124 participants
Enrollment target

Study Summary

The CERAMICS study is designed to more clearly delineate the current care of acute myocardial infarction with cardiogenic shock (AMICS) patients who are treated with mechanical circulatory support (MCS) devices in the United States with significant experience in MCS, all of whom have the capability of MCS escalation on-site. Study enrollment is targeted at 120 patients at 20 hospital sites, evaluating clinical outcomes, and focusing on outcomes MCS escalation decision making and ICU level management.

Primary Outcome

Hospital discharge survival/survival at 30 days

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2022-07-22
Est. Completion 2026-12-31
Henry Ford Health System

234 total trials

What the registry record for NCT05800951 still lists

NCT05800951 is an observational study that tracks outcomes without assigning an intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT05800951 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05800951 about?

NCT05800951 is a clinical study titled "Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock". The CERAMICS study is designed to more clearly delineate the current care of acute myocardial infarction with cardiogenic shock (AMICS) patients who are treated with mechanical circulatory support (MCS) devices in the United States with significant experience in MCS, all of whom have the capability ...

What is the current status of trial NCT05800951?

This trial is currently active not recruiting. The enrollment target is 124 participants. The study started on 2022-07-22. Estimated completion is 2026-12-31.

Who is sponsoring clinical trial NCT05800951?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523014 · 124 participants · Phase 2

    Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

  • NCT02670707 · 124 participants · Phase 3

    Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

  • NCT02830724 · 124 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

  • NCT04748809 · 124 participants · NA

    Effect of Anti-inflammatory Diet in Rheumatoid Arthritis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05800951, the US trial registry maintained by the National Library of Medicine. NCT05800951 (mid enrollment · none site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.